{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:47:08Z","timestamp":1777398428325,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Angiology"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p>Policosanol is a cholesterol-lowering drug with concomitant antiplatelet effects. The present study was undertaken to compare the effects of policosanol and ticlopidine in patients with moderately severe intermittent claudication (IC). The study had a 4-week baseline step, followed by a 20-week double-blinded, randomized treatment period. Twenty-eight eligible patients were randomized to policosanol 10 mg or ticlopidine 250 mg tablets twice daily (bid). Walking distances in a treadmill (constant speed 3.2 km\/hr, slope 10\u00b0, temperature 25\u00b0C) were assessed before and after 20 weeks of treatment. Both groups were similar at baseline. Compared with baseline, policosanol significantly increased (p&lt;0.01) mean values of initial (ICD) and absolute (ACD) claudication distances from 162.1 to 273.2 m and from 255.8 to 401.0 m, respectively. Ticlopidine also raised significantly (p&lt;0.01) ICD (166.2 to 266.3 m) and ACD (252.9 to 386.4 m). Comparisons between groups did not show significant differences. Policosanol, but not ticlopidine, significantly (p&lt;0.05), but modestly, increased the ankle\/arm pressure ratio. After 10 weeks, policosanol significantly (p&lt;0.001) lowered low-density lipoprotein-cholesterol (LDL-C), total cholesterol (TC) (p&lt;0.01), and TC\/HDL-C and raised (p&lt;0.05) high-density lipoprotein-cholesterol (HDL-C). At study completion, policosanol lowered (p&lt;0.001) LDL-C (30.2%), TC (16.9%), and TC\/HDL-C (33.9%), increased (p&lt;0.01) HDL-C (+31.7%), and left triglycerides unchanged. Ticlopidine did not affect the lipid profile variable. Policosanol induced modest, but significant, reductions (p&lt;0.01) of fibrinogen levels compared with baseline and ticlopidine. Treatments were well tolerated and did not impair safety indicators. Three ticlopidine patients (21.4%) withdrew from the trial, only 1 owing to a serious adverse experience (AE) (unstable angina). Three other ticlopidine patients experienced mild AE (headache, diarrhea, and acidity). It is concluded that policosanol (10 mg bid) can be as effective as ticlopidine (250 mg bid) for improving walking distances of claudicant patients, and it could be advantageous for the global risk of these individuals owing to its cholesterol-lowering effects. This study is, however, just a pilot comparison, so that further studies in larger sample sizes are needed for definitive conclusions of the comparative effects of both drugs on patients with IC.<\/jats:p>","DOI":"10.1177\/000331970405500403","type":"journal-article","created":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T16:26:23Z","timestamp":1143822383000},"page":"361-371","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Policosanol and Ticlopidine in Patients with Intermittent Claudication: A Double-Blinded Pilot Comparative Study"],"prefix":"10.1177","volume":"55","author":[{"given":"Gladys","family":"Casta\u00f1o","sequence":"first","affiliation":[{"name":"Medical Surgical Research Center, Havana City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"M\u00e1s","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana City, Cuba,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"G\u00e1mez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana City, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana City, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Illnait","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana City, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,7]]},"reference":[{"key":"e_1_2_1_1_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856003-00001"},{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199406030-00003"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07492-2"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856003-00004"},{"key":"e_1_2_1_5_1","first-page":"268 B","article-title":"The ankle arm index as a predictor of cardiovascular events and death in the general population","volume":"13","author":"Fowkes FGR","year":"1997","unstructured":"Fowkes FGR, Leng GC, Lee AJ, et al: The ankle arm index as a predictor of cardiovascular events and death in the general population. Can J Cardiol 13(suppl B):268 B, 1997.","journal-title":"Can J Cardiol"},{"key":"e_1_2_1_5_2","volume-title":"4th International Conference on Preventive Cardiology","unstructured":"Abstracts of the 4th International Conference on Preventive Cardiology."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260605"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-821X(05)80676-0"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116294"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.6.1915"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117264"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2481"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800691309"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331978403500701"},{"key":"e_1_2_1_14_1","first-page":"371","article-title":"Double-blind, controlled multicenter study of indubofen versus placebo in patients with intermittent claudication","volume":"12","author":"Tonnesen KH","year":"1993","unstructured":"Tonnesen KH, Albuquerque P, Baitsch G, et al: Double-blind, controlled multicenter study of indubofen versus placebo in patients with intermittent claudication. Int Angiol 12:371-377, 1993.","journal-title":"Int Angiol"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.4_Supplement.431S"},{"key":"e_1_2_1_16_1","first-page":"21","article-title":"Platelets in peripheral arterial disease","volume":"4","author":"Verhaeghe R","year":"1994","unstructured":"Verhaeghe R: Platelets in peripheral arterial disease. Crit Ischaemia 4:21-25, 1994.","journal-title":"Crit Ischaemia"},{"key":"e_1_2_1_17_1","first-page":"222","article-title":"Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states","volume":"34","author":"Saltiel E","year":"1987","unstructured":"Saltiel E, Ward A: Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 34:222-226, 1987.","journal-title":"Drugs"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)80077-5"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900912"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331978803900904"},{"key":"e_1_2_1_21_1","first-page":"14","article-title":"Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs","volume":"77","author":"Cloarec M","year":"1988","unstructured":"Cloarec M, Arcan JC, Caillard PH, et al: Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Angiologie 77(suppl):14-18, 1988.","journal-title":"Angiologie"},{"key":"e_1_2_1_22_1","first-page":"84","article-title":"Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial","volume":"114","author":"Balsano F","year":"1989","unstructured":"Balsano F, Cocheri S, Libretti A, et al: Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial. J Lab Clin Med 114:84-88, 1989.","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646882"},{"key":"e_1_2_1_24_1","first-page":"301","article-title":"Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study","volume":"227","author":"Janzon L","year":"1990","unstructured":"Janzon L, Bergqvist D, Boberg J, et al: Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. Scand J Med 227:301-310, 1990.","journal-title":"Scand J Med"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2000.025.06.574693"},{"key":"e_1_2_1_26_1","first-page":"27","article-title":"Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment","volume":"14","author":"Pons P","year":"1994","unstructured":"Pons P, Rodr\u00edguez M, Robaina C, et al: Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 14:27-33, 1994.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_1_27_1","first-page":"159","article-title":"A two-year study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia","volume":"15","author":"Canetti M","year":"1995","unstructured":"Canetti M, Morera M, Illnait J, et al: A two-year study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 15:159-165, 1995.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(96)80068-3"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(97)80099-9"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70139-6"},{"key":"e_1_2_1_31_1","first-page":"105","article-title":"Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients","volume":"19","author":"Casta\u00f1o G","year":"1999","unstructured":"Casta\u00f1o G, M\u00e1s R, Arruzazabala ML, et al: Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res 19:105-116, 1999.","journal-title":"Int J Clin Pharm Res"},{"key":"e_1_2_1_32_1","first-page":"1","article-title":"Effect of policosanol on postmenopausal women with type II hypercholesterolemia","volume":"13","author":"Casta\u00f1o G","year":"2000","unstructured":"Casta\u00f1o G, M\u00e1s R, Fern\u00e1ndez L, et al: Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 13:1-9, 2000.","journal-title":"Gynecol Endocrinol"},{"key":"e_1_2_1_33_1","first-page":"43","article-title":"Effects of policosanol 20 versus 40 mg\/day in the treatment of patients with type II hypercholesterolemia: A 6-month double-blind study","volume":"21","author":"Casta\u00f1o G","year":"2001","unstructured":"Casta\u00f1o G, Mas R, Fern\u00e1ndez L, et al: Effects of policosanol 20 versus 40 mg\/day in the treatment of patients with type II hypercholesterolemia: A 6-month double-blind study. Int J Clin Pharmacol Res 21:43-58, 2001.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200121070-00004"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200203030-00004"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.3.393"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(97)80077-X"},{"key":"e_1_2_1_38_1","first-page":"105","article-title":"Comparative study of the efficacy, tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus","volume":"19","author":"Crespo N","year":"1999","unstructured":"Crespo N, Illnait J, Mas R, et al: Comparative study of the efficacy, tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 19:105-116, 1999.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(93)90030-R"},{"key":"e_1_2_1_40_1","first-page":"17","article-title":"Estudio farmacol\u00f3gico de la interacci\u00f3n entre el policosanol y la aspirina en animales de experimentaci\u00f3n","volume":"5","author":"Arruzazabala ML","year":"1992","unstructured":"Arruzazabala ML, Carbajal D, Molina V, et al: Estudio farmacol\u00f3gico de la interacci\u00f3n entre el policosanol y la aspirina en animales de experimentaci\u00f3n. Rev Iberoam Tromb Hemost 5:17-20, 1992.","journal-title":"Rev Iberoam Tromb Hemost"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1996.0086"},{"key":"e_1_2_1_42_1","first-page":"58","article-title":"Efecto del policosanol sobre la funci\u00f3n de las plaquetas en voluntarios sanos","volume":"9","author":"Scazziota A","year":"1996","unstructured":"Scazziota A, Pons S, Altman R: Efecto del policosanol sobre la funci\u00f3n de las plaquetas en voluntarios sanos. Rev Iberoam Tromb Hemost 9:58-62, 1996.","journal-title":"Rev Iberoam Tromb Hemost"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-3278(98)90130-2"},{"key":"e_1_2_1_44_1","first-page":"32","article-title":"Niveles plasm\u00e1ticos y excreci\u00f3n de la radiactividad total en voluntarios sanos tras la administraci\u00f3n oral de octacosanol-3H","volume":"27","author":"Men\u00e9ndez R","year":"1996","unstructured":"Men\u00e9ndez R, Sotolongo V, Fraga V, et al: Niveles plasm\u00e1ticos y excreci\u00f3n de la radiactividad total en voluntarios sanos tras la administraci\u00f3n oral de octacosanol-3H. Rev CENIC Cien Biol 27:32-35, 1996.","journal-title":"Rev CENIC Cien Biol"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331979905000205"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331970305400104"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331970105200205"},{"key":"e_1_2_1_48_1","first-page":"525","article-title":"The evaluation of exercise performance in patients with peripheral vascular disease","volume":"12","author":"Latt WR","year":"1998","unstructured":"Latt WR, Nawaz D, Regensterner JG, et al: The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil 12:525-532, 1998.","journal-title":"J Cardiopulm Rehabil"},{"key":"e_1_2_1_49_1","first-page":"339","article-title":"Guidelines for therapeutic studies on peripheral arterial occlusive disease in Fontaine stages II-IV","volume":"21","author":"Heidrich H","year":"1992","unstructured":"Heidrich H, Allenberg J, Cachovan M, et al: Guidelines for therapeutic studies on peripheral arterial occlusive disease in Fontaine stages II-IV. Vasa 21:339-343, 1992.","journal-title":"Vasa"},{"key":"e_1_2_1_50_1","first-page":"1405","article-title":"Second report of the Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). III Drug treatment","volume":"89","author":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults","year":"1994","unstructured":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program (NCEP): Second report of the Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). III Drug treatment. Circulation 89:1405-1419; 1432-1445, 1994.","journal-title":"Circulation"},{"key":"e_1_2_1_51_1","first-page":"1300","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Task force of he European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension","volume":"15","author":"Pyorala K","year":"1994","unstructured":"Pyorala K, De Backer G, Graham I, et al, on behalf of the Task Force: Prevention of coronary heart disease in clinical practice. Recommendations of the Task force of he European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur Heart J 15:1300-1331, 1994;","journal-title":"Eur Heart J"},{"key":"e_1_2_1_51_2","first-page":"116","volume":"110","year":"1994","unstructured":"and Atherosclerosis 110:116-121, 1994.","journal-title":"Atherosclerosis"},{"key":"e_1_2_1_52_1","first-page":"66","volume-title":"The International Lipid Information Bureau (ILIB): Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease","author":"Gotto A","year":"2000","unstructured":"Gotto A, Assmann G, Carmena R, et al: The International Lipid Information Bureau (ILIB): Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease, ed. 2. New York: International Lipid Information Bureau, 2000, p 66.","edition":"2"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162405"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.9.3037"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89459-4"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/27.6.838"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"}],"container-title":["Angiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/000331970405500403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/000331970405500403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:13:16Z","timestamp":1777371196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/000331970405500403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1177\/000331970405500403"],"URL":"https:\/\/doi.org\/10.1177\/000331970405500403","relation":{},"ISSN":["0003-3197","1940-1574"],"issn-type":[{"value":"0003-3197","type":"print"},{"value":"1940-1574","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}